SEARCH

SEARCH BY CITATION

References

  • 1
    Ohkubo T, Imai Y, Tsuji I, et al.Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens.1998;16:971975.
  • 2
    Sega R, Facchetti R, Bombelli M, et al.Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the pressioni arteriose monitorate e loro associazioni (pamela) study. Circulation.2005;111:17771783.
  • 3
    Kario K, Pickering TG, Matsuo T, et al.Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension.2001;38:852857.
  • 4
    Ohkubo T, Asayama K, Kikuya M, et al.Prediction of ischaemic and haemorrhagic stroke by self-measured blood pressure at home: the Ohasama study. Blood Press Monit.2004;9:315320.
  • 5
    Agarwal R, Andersen MJ. Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease. Kidney Int.2006;69:406411.
  • 6
    Palatini P, Benetos A, Grassi G, et al.Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension consensus meeting. J Hypertens.2006;24:603610.
  • 7
    Gillman MW, Kannel WB, Belanger A, et al.Influence of heart rate on mortality among persons with hypertension: the Framingham study. Am Heart J.1993;125:11481154.
  • 8
    Ogihara T, Kano T, Kakinuma C. Evaluation of the inhibitory effect of dihydropyridines on n-type calcium channel by virtual three-dimensional pharmacophore modeling. Arzneimittelforschung.2009;59:283288.
  • 9
    Takahara A. Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther.2009;27:124139.
  • 10
    Takahara A, Koganei H, Takeda T, et al.Antisympathetic and hemodynamic property of a dual l/n-type Ca(2+) channel blocker cilnidipine in rats. Eur J Pharmacol.2002;434:4347.
  • 11
    Takahara A, Iwasaki H, Nakamura Y, et al.Cardiac effects of l/n-type Ca2+ channel blocker cilnidipine in anesthetized dogs. Eur J Pharmacol.2007;565:166170.
  • 12
    Sakata K, Shirotani M, Yoshida H, et al.Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Hypertension.1999;33:14471452.
  • 13
    Kosaka T, Nakagawa M, Ishida M, et al.Cardioprotective effect of an l/n-type calcium channel blocker in patients with hypertensive heart disease. J Cardiol.2009;54:262272.
  • 14
    Tomiyama H, Kimura Y, Kuwabara Y, et al.Cilnidipine more highly attenuates cold pressor stress-induced platelet activation in hypertension than does amlodipine. Hypertens Res.2001;24:679684.
  • 15
    Eguchi K, Kario K, Shimada K. Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients. Hypertens Res.2002;25:329333.
  • 16
    Eguchi K, Kario K, Hoshide Y, et al.Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients. Am J Hypertens.2004;17:112117.
  • 17
    Ishimitsu T, Minami J, Yoshii M, et al.Comparison of the effects of amlodipine and losartan on 24-hour ambulatory blood pressure in hypertensive patients. Clin Exp Hypertens.2002;24:4150.
  • 18
    Nagahama S, Norimatsu T, Maki T, et al.The effect of combination therapy with an l/n-type Ca(2+) channel blocker, cilnidipine, and an angiotensin II receptor blocker on the blood pressure and heart rate in Japanese hypertensive patients: an observational study conducted in Japan. Hypertens Res.2007;30:815822.
  • 19
    Yamagishi T. Beneficial effect of cilnidipine on morning hypertension and white-coat effect in patients with essential hypertension. Hypertens Res.2006;29:339344.
  • 20
    Imai Y, Otsuka K, Kawano Y, et al.Japanese Society of Hypertension (JSH) guidelines for self-monitoring of blood pressure at home. Hypertens Res.2003;26:771782.
  • 21
    Hozawa A, Ohkubo T, Kikuya M, et al.Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. Am J Hypertens.2004;17:10051010.
  • 22
    Nauman J, Janszky I, Vatten LJ, et al.Temporal changes in resting heart rate and deaths from ischemic heart disease. JAMA.2011;306:25792587.
  • 23
    Ishikawa J, Kario K, Hoshide S, et al.Determinants of exaggerated difference in morning and evening blood pressure measured by self-measured blood pressure monitoring in medicated hypertensive patients: Jichi morning hypertension research (J-MORE) study. Am J Hypertens.2005;18:958965.
  • 24
    Kario K, Odawara M, Kimura K, et al.Nearly half of uncontrolled hypertensive patients could be controlled by high-dose titration of amlodipine in the clinical setting: the Achieve study. Curr Hypertens Rev.2011;7:102110.
  • 25
    Schofl C, Becker C, Prank K, et al.Twenty-four-hour rhythms of plasma catecholamines and their relation to cardiovascular parameters in healthy young men. Eur J Endocrinol.1997;137:675683.
  • 26
    Marfella R, Gualdiero P, Siniscalchi M, et al.Morning blood pressure peak, qt intervals, and sympathetic activity in hypertensive patients. Hypertension.2003;41:237243.
  • 27
    Kario K. Morning surge in blood pressure and cardiovascular risk: evidence and perspectives. Hypertension.2000;56:765773.
  • 28
    White WB. Importance of blood pressure control over a 24-hour period. J Manag Care Pharm.2007;13:3439.
  • 29
    Palatini P. Role of elevated heart rate in the development of cardiovascular disease in hypertension. Hypertension.2000;58:745750.
  • 30
    Fox K, Borer JS, Camm AJ, et al.Resting heart rate in cardiovascular disease. J Am Coll Cardiol.2007;50:823830.
  • 31
    Swedberg K, Komajda M, Bohm M, et al.Ivabradine and outcomes in chronic heart failure (shift): a randomised placebo-controlled study. Lancet.2000;376:875885.
  • 32
    Tanaka M. The l/n-type calcium channel blocker, cilnidipine, reduces heart rate and albuminuria in patients with type 2 diabetes. J Int Med Res.2000;38:602610.
  • 33
    Habeler G, Lenzhofer R, Pall H, et al.[Effectiveness and tolerance of amlodipine in treatment of patients with mild to moderate hypertension. Results of a long-term study with a new calcium antagonist]. Wien Klin Wochenschr.1992;104:1620.
  • 34
    Fogari R, Mugellini A, Zoppi A, et al.Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens.2003;16:596599.
  • 35
    Lohmeier TE, Iliescu R, Liu B, et al.Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension.2000;59:331338.
  • 36
    Fujita T, Ando K, Nishimura H, et al.Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int.2007;72:15431549.